- US-listed companies
- Cue Biopharma, Inc.
Cue Biopharma, Inc.CUE
Market cap
$77.16M
P/E ratio
Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Collaboration revenue | - | 3 | 3 | 15 | 1 |
General and administrative | - | 13 | 15 | 17 | 16 |
Research and development | - | 27 | 34 | 41 | 39 |
Gain On Right Of Use Asset Termination | - | - | - | - | 276,633 |
Total operating expenses | - | 40 | 48 | 59 | 54 |
Loss from operations | - | -36,769,247 | -45,042,585 | -43,712,073 | -53,224,809 |
Interest income | - | 418,712 | 463,914 | 45,898 | 928,242 |
Interest expense | - | - | - | - | -713,815 |
Total other income | - | 482,790 | 463,914 | 45,898 | 214,427 |
Loss before provision for income taxes | - | -36,286,457 | -44,578,671 | -43,666,175 | -53,010,382 |
Provision for income taxes | - | 412,500 | 206,250 | 495,000 | - |
Net loss | -38,980,313 | -36,698,957 | -44,784,921 | -44,161,175 | -53,010,382 |
Unrealized (loss) gain from available-for-sale securities | - | 637 | 17,452 | -7,131 | -95,873 |
Comprehensive loss | - | -36,698,320 | -44,767,469 | -44,168,306 | -53,106,255 |
Earnings Per Share, Basic | - | - | - | - | -1.49 |
Earnings Per Share, Diluted | - | - | - | - | -1.49 |